Summarized by Masters of Longevity from PR Newswire.
Research-focused article about a collaboration producing early real-world evidence on an oral GLP-1 treatment; it previews upcoming conference presentations and ongoing analyses.
Key Takeaways
- Ro and Novo collaborated to generate real-world evidence on patients switching from injectable GLP‑1s to the Wegovy pill.
- Initial results evaluating patients persistent on the Wegovy pill for three months were presented at EASD 2026.
- Additional analyses on patient demographics, weight loss, food noise, and quality of life will be presented at ObesityWeek 2026.
